Fiskars' Q4 results were in line with expectations and the company issued positive guidance for 2025...
Redeye reinforces its positive view of Transtema following a strong Q4, where Sweden improved substa...
Analysguiden ser ljust på framtiden för Eastnine efter årets två förvärv i Polen.
On February 6th, Eevia Health published the Company’s quarterly report for Q4-24.
DT’s Q4 results came in largely as expected as EBITA improved by EUR 0.
LapWall's fourth quarter performance was solid, despite net sales falling 13% y/y.
Redeye provides a research note on Faron Pharmaceuticals following the outcome of the company’s rece...
Redeye presents its preview for Devyser’s Q4 2024 report, due on February 13.
Redeye’s view on the Q4 report. The organic growth was weak, with large swings in the development in...
Redeye continues to be positive to Bredband2 following a Q4 report in line with our estimates, posti...
Redeye comments on Göran Forsberg leaving as CEO with Damian Marron from the board taking the role ...
Redeye comments on Alligator Bioscience's end of phase II meeting with the American regulatory autho...
Redeye returns following Elicera's Q4 report and recent news in the company.
Redeye comments on Tessin’s Q4 results, which were softer than expected.
EBIT SEK -28m vs. ABG SEK -25m — lower volumes Q1 likely better — no maintenance Conference call at ...
Sales +36% and EBIT +82% vs. ABGSCe Expect cons. to raise '25e-'26e sales by ~15% Overall a strong b...
Fiskars’ net sales continued the decreasing trend y/y in both Business Areas due to low consumer con...
Sales SEK 630m, -15% vs. ABGSCe EBIT of SEK 51m, -5% vs.
Redeye comments on I-Tech’s Q4 figures that significantly beat our estimates across the board, prima...
After a period of steady increase in both European Idefirix sales and patient usage, Hansa records a...